^
Association details:
| Biomarker: | EGFR mutation + NRAS Q61K |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
Excerpt:
...we introduced cDNAs encoding NRAS Q61K or BRAF G469A in PC-9 cells and BRAF V600E in both PC-9 and PC-9R cells and treated cell transfectants with various inhibitors….Ectopic expression of these mutants but not their wild-type counterparts led to constitutive pERK activation, even in the presence of erlotinib or afatinib...Consistent with these data, EGFR-mutant cells with stable expression of either mutant were resistant to growth inhibition by erlotinib...
DOI:
https://doi.org/10.1073/pnas.1203530109
